Elutia Inc
NASDAQ:ELUT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Elutia Inc
NASDAQ:ELUT
|
US |
|
Red Mountain Mining Ltd
ASX:RMX
|
AU |
Elutia Inc
Aziyo Biologics, Inc. operates as a biotechnology company. The company is headquartered in Silver Spring, Maryland and currently employs 151 full-time employees. The company went IPO on 2020-10-08. The firm is a commercial-stage company that serves two markets with products based on its biomatrix platforms. The company offers a drug-eluting biologic technology: a fusion of natural biologic material and extended antibiotic release, for device implantation and soft tissue reconstruction. Its first product is CanGaroo Envelope, used for the stabilization of implantable cardiac devices, such as pacemakers and defibrillators. Its second product is SimpliDerm Acellular Dermal Matrix, used primarily in breast reconstruction following mastectomy. The company is also engaged in the development of CanGaroo RM, which adds the antibiotics rifampin and minocycline for sustained delivery directly to the surgical site. The Company’s products are used by electrophysiologists and plastic surgeons.
Aziyo Biologics, Inc. operates as a biotechnology company. The company is headquartered in Silver Spring, Maryland and currently employs 151 full-time employees. The company went IPO on 2020-10-08. The firm is a commercial-stage company that serves two markets with products based on its biomatrix platforms. The company offers a drug-eluting biologic technology: a fusion of natural biologic material and extended antibiotic release, for device implantation and soft tissue reconstruction. Its first product is CanGaroo Envelope, used for the stabilization of implantable cardiac devices, such as pacemakers and defibrillators. Its second product is SimpliDerm Acellular Dermal Matrix, used primarily in breast reconstruction following mastectomy. The company is also engaged in the development of CanGaroo RM, which adds the antibiotics rifampin and minocycline for sustained delivery directly to the surgical site. The Company’s products are used by electrophysiologists and plastic surgeons.
Revenue: Reported $3.3 million in Q4 revenue, up 16% from $2.8 million a year ago, driven by return to direct distribution.
Margins: Adjusted gross margin improved to 66.8% from 56.5% a year ago (up 12 percentage points).
Cash & balance sheet: $44.4 million in cash on hand plus $8 million in escrow; paid off SWK debt (~$28 million) after selling BioEnvelope.
Pipeline & timing: Submitted NXT-41 to FDA; company expects clearance for NXT-41 toward the end of the first half of 2026 and anticipates NXT-41x clearance and a second-half 2026 launch.
Market opportunity: Targeting breast reconstruction, a $1.5 billion market with ~162,000 reconstructions annually and high infection rates (registry 12%–37%; company cites 15%–20%).
Strategic moves: Hired new CCO Pete Ligotti and added board member Guido Neels; exploring strategic options for SimpliDerm to focus resources on 41x.
Clinical potential: Management highlighted prior studies showing local antibiotic delivery reduced infections 62% and 82% in different cohorts and said they aim for sustained local antibiotic coverage (~30 days) to reduce postoperative infections.
